Influences of Sex and Estrogen in Arterial and Valvular Calcification

Bin Zhang1,2, Virginia M. Miller1,3 and Jordan D. Miller1,2,3,4*

1 Department of Surgery, Mayo Clinic, Rochester, MN, United States, 2 Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States, 3 Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States, 4 Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, United States

Vascular and cardiac valvular calcification was once considered to be a degenerative and end stage product in aging cardiovascular tissues. Over the past two decades, however, a critical mass of data has shown that cardiovascular calcification can be an active and highly regulated process. While the incidence of calcification in the coronary arteries and cardiac valves is higher in men than in age-matched women, a high index of calcification associates with increased morbidity, and mortality in both sexes. Despite the ubiquitous portending of poor outcomes in both sexes, our understanding of mechanisms of calcification under the dramatically different biological contexts of sex and hormonal milieu remains rudimentary. Understanding how the critical context of these variables inform our understanding of mechanisms of calcification—as well as innovative strategies to target it therapeutically—is essential to advancing the fields of both cardiovascular disease and fundamental mechanisms of aging. This review will explore potential sex and sex-steroid differences in the basic biological pathways associated with vascular and cardiac valvular tissue calcification, and potential strategies of pharmacological therapy to reduce or slow these processes.

Keywords: age-related cardiovascular parameters, aging, aortic valve stenosis, cardiovascular calcification, epidemiology, estrogen, hemodynamics, testosterone

BACKGROUND

Ectopic calcification in cardiovascular tissue was once considered to be a passive consequence of cardiovascular disease processes with increasing age. The association-based clinical observations driving this model painted a remarkably appealing picture, with vascular calcification being evident in roughly 25% of patients at age of 50 years, and soaring to over 60% in patients over the age of 75 years (1). While the incidence of aortic valve calcification was slightly lower, the overall trend for dramatic, age-associated increases was equally robust. From such population-based studies, risk factors for vascular and valvular calcification quickly emerged, include aging, metabolic syndrome, smoking, and male sex (2–5).

The site-specific mechanisms of ectopic calcification within the tissues of the cardiovascular system are incompletely understood. At present, calcification in either the coronary arteries or cardiac valves is often considered an organized, regulated, and active pathological process, with evidence of many molecular pathways paralleling those observed in bone/orthotopic ossification. Despite this apparent conservation of core osteoblastic signaling pathways, mature bone matrix is rarely found in calcifying cardiovascular tissues (6–8). Critically, however, upstream mechanisms regulating the induction and amplification of these signaling pathways are likely to be
fundamentally different between cardiovascular and orthotopic tissues, since exposure to oxidative stress amplifies osteogenic signaling in calcifying cardiovascular cells but markedly suppresses calcification in bone-derived osteoblasts (9). Furthermore, the contribution of dystrophic tissue calcification—where amorphous accumulation of calcium occurs in the absence of bone matrix, functional osteogenic signaling, or presence of osteoblast-like cells—remains remarkably elusive in the pathogenesis of aortic valve stenosis.

In recent years, tissue fibrosis emerged as a potential and major contributor to aortic valve dysfunction in experimental animals. In particular, genetically altered mice with a propensity for both hypertension and hyperlipidemia developed hemodynamically-significant aortic valve stenosis associated with structural and molecular changes consistent with activation of fibrogenic signaling, and critically, in the absence of substantive changes in valvular calcification. Consequently, investigation into the role of fibrosis as a clinically-meaningful determinant of the degree of valvular stenosis is an exciting and emerging field.

THE CLINICAL JUSTIFICATION FOR EXPLORING THE ROLE OF SEX IN CAVD

While a number of retrospective studies led many to conclude that “women are protected against aortic valve stenosis by estrogens” (10–12), recent work suggests that the pathobiology underlying the disease process may be fundamentally different. For instance, in aortic valve disease—where calcification was once thought to be the primary and near exclusive driver of valve dysfunction—men had more calcification than women at any given level of valvular stenosis (even after normalizing for body size or aortic root size) (13–15), suggesting that valvular fibrosis may play a greater role in determining cusp movement in women compared to men. Similarly, the site of cardiovascular calcification seems to play an important role in predicting mortality in a sex-dependent manner, with thoracic aortic calcification being a strong predictor of mortality secondary to coronary events predominantly in women (16), whereas thoracic aortic and abdominal aortic calcification are strong predictors of all-cause mortality in men (17).

Collectively, the observation that men have higher prevalence of calcification in atherosclerotic lesions and cardiac valves compared to women at any given decade of life has been an interesting clinical observation, and the biological underpinnings and collective clinical implications of these observations are likely to be of great value in developing sex-specific pharmacological treatments to prevent clinically significant valvular and vascular pathology and dysfunction (15, 18, 19). Herein, we aim to highlight potential cellular mechanisms modulated by sex and sex steroid hormones contributing to key sex differences in cardiovascular calcification, with an overall aim of driving dialogue around critical unanswered questions in the field.

MOLECULAR SIGNALING INVOLVED IN CARDIOVASCULAR CALCIFICATION: AN INITIAL SEX AND SEX HORMONE AGNOSTIC PERSPECTIVE

While calcification in the cardiovascular system is often considered an active, regulated process with activation of many fundamental osteogenic signaling cascades being conserved between ectopic cardiovascular calcification and orthotopic bone ossification, upstream mechanisms contributing to the induction, sustained activation, and amplification of these pathways can differ markedly. Interestingly, even during formation of micro-calcific deposits there is expression of proteins which are usually absent (e.g., osteopontin) and/or overexpression of proteins which are usually very low in local tissue (e.g., matrix Gla protein), suggesting that maladaptive processes may be initiated even in the earliest stages of the disease (4, 5, 14, 20, 21). Several of the major molecular signaling pathways involved in regulation of ectopic calcification are ubiquitously active in both males and females (Figure 1).

Transforming Growth Factor-β (TGF-β) Signaling

One of the most extensively studied pathways in calcific vascular and valvular disease is TGF-β pathway. While the downstream effects are remarkably context dependent (and in vitro are dependent on substrate stiffness), TGF-β most often induces cell migration, proliferation, and extracellular matrix protein elaboration. Critically, on stiff substrates and matrices, TGFβ robustly induces apoptosis and dystrophic calcific nodule formation in aortic valve interstitial cells from a variety of species, suggesting that the matrix accumulation and sclerosis occurring in early stages of valvular heart disease may shift the phenotypic consequences of increased TGF-β across the spectrum of the disease and contribute to both fibrosis and dystrophic calcification to different extents during the evolution of disease (22, 23).

BMP Signaling

Bone morphogenetic proteins (BMPs), members of the TGF-β superfamily, are significantly increased in ectopic calcification lesions within the cardiovascular system including valvular and vascular tissues (22, 24, 25). Initiated by seminal observations from Demer et al., nearly two decades of work have generated compelling data that BMP signaling plays an integral role in the initiation and progression of cardiovascular calcification. Most paradigms implicating BMP signaling suggest that these morphogens serve as a paracrine signal from nearby resident cells to drive osteogenesis via a BMP-Msx2-Wnt cascade (26–28). Importantly, mechanical stimuli—including non-laminar blood flow patterns exacerbated by multiple disease states—induce both oxidative stress and BMP elaboration from vascular and valvular endothelial cells (29, 30). Furthermore, BMP2- and BMP4-driven osteogenic signaling can be further augmented in conditions...
FIGURE 1 | Effects of estrogens and androgen signaling on multiple cellular processes implicated in the regulation of cardiovascular calcification. Note that estrogen can bind to estrogen receptors (ER, resulting in nuclear translation), G-protein coupled estrogen receptors (GPER, eliciting cytosolic signaling), and estrogen binding proteins (EBPs, eliciting cytosolic signaling) to exert a variety of effects—both positive and negative—on molecules influencing ectopic calcification. In general, androgens bind to androgen receptors (AR) and have a smaller number of signal transducing elements compared to estrogens. Abbreviations and impact on calcification: RANKL, receptor activator of nuclear factor κB ligand (promotes calcification); PPARγ, peroxisome proliferator-activated receptor-γ (prevents calcification); NFκB, nuclear factor κB (promotes inflammation/calcification); NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase (increases oxidative stress/calcification); SOD, superoxide dismutase (reduces oxidative stress/calcification); O₂•−, superoxide anion (increases calcification); p53, tumor protein 53 (promotes inflammation/calcification).

where endogenous inhibitors (such as matrix Gla protein) are reduced or absent in a variety of disease states (31).

It is noteworthy that not all bone morphogenetic proteins drive ectopic tissue calcification. For example, BMP-7, which is found in human vascular calcification, slows the progression of arterial calcification in both human and mice with diabetes and hyperlipidemia (32, 33). It is also important to note that while the context dependence of TGF-β signaling has been well-defined by numerous investigators, the role of cell-substrate interactions in the phenotypic consequence of BMP signaling has received much less attention in the literature.

Wnt/β-Catenin Signaling
While increased TGF-β superfamily signaling is a near ubiquitous finding in calcifying cardiovascular tissues, numerous investigators have reported upregulation of other signaling pathways central in bone ossification in diseased vascular and valvular tissues (34). One such pathway is Wnt/β-catenin signaling, where multiple reports have documented increases in Wnt ligand elaboration, low-density lipoprotein receptor-related protein (LRP) receptor components, hyperactivation of canonical β-catenin signaling components, and upregulation of β-catenin transcriptional targets (35, 36).

The Role of Extracellular Vesicles in Cardiovascular Calcification
Recently, numerous studies have implicated extracellular vesicles in the initiation and progression of cardiovascular calcification (37–39). While their precise role remains largely unclear, several studies reported accumulation of nanoparticles that appear to precede (or occur concomitantly) with induction of osteogenic signals in cardiovascular tissue, and aggregation of such vesicles can contribute to formation of larger calcific masses at multiple cardiovascular sites (40–42). Unlike bone, however, where matrix vesicles are derived largely from chondrocytes and osteoblasts, extracellular vesicles accumulating in the cardiovascular system appear to be derived from vascular smooth muscle cells and/or immune cells/macrophages (43, 44). While the composition of each vesicle subset has yet to be comprehensively characterized, it is likely that the cell origin, mechanism/driver of release, vesicle contents, and target tissue in which deposition occurs are all likely determinants of phenotypic/biological outcomes (45, 46).

The Site-Specific Role of Inflammation in Ectopic and Orthotopic Calcification
Tumor necrosis factor-α (TNF-α) is a major cytokine involved in driving both local and systemic inflammation in a variety
of cardiovascular pathologies. Thus, it is not surprising that upregulation of TNFα has been shown to augment multiple pathophysiological intracellular signaling cascades involved with vascular and valvular calcification, including interactions with BMP signaling, Msx2-dependent gene transcription, and both canonical and non-canonical Wnt/β-catenin signaling (35, 47–49). For example, the presence of a TNF-α-Msx2–Wnt/β-catenin cascade acts as a major driver of calcium deposition in aortic valve interstitial cells in vitro (48, 49) and in atherosclerotic lesions in hyperlipidemic mice in vivo (50). While additional mechanistic studies have suggested that antibody-mediated neutralization of TNFα may be effective at slowing initiation or progression of plaque calcification through attenuation of Wnt/β-catenin signaling (3, 50), systemic, long-term suppression of TNFα also puts patients at risk of being immunocompromised, and development of fatal infections.

**IMPACT OF SEX HORMONES ON PROCESSES OF CALCIFICATION**

Although the overall lifetime incidence of atherosclerosis, aortic stenosis, and cumulative death from cardiovascular diseases are remarkably comparable between men and women (51, 52), the primary contributor to the perception of reduced CVD burden in women is the delay in prevalence of atherosclerosis and/or aortic valve stenosis in women compared to men at each decade of life (53, 54). Our understanding of the impact of sex hormones on cardiovascular calcification is compounded by several factors, including marked differences in sex hormone levels over the lifespan of men and women, the effect, type, and timing of hormone replacement on cardiovascular biology in women, and the general paucity of appropriately powered clinical trial data evaluating differential efficacy and effectiveness of drug interventions on men and women. This understanding is complicated further by the fact that many pre-clinical studies have not actively considered the role of sex in the biological pathways being interrogated (via the exclusion of female animals) or have not faithfully recaptured changes in hormones similar to that observed over the lifespan of humans. Given these caveats, we will address the potential roles of both estrogens and androgens on cardiovascular calcification by first providing limited insights from clinical observations, followed by mechanistic insights gleaned largely from pre-clinical animal models.

**ROLE OF ESTROGENS IN THE REGULATION OF CARDIOVASCULAR CALCIFICATION**

**Clinical Observations**

Several seminal studies reported that post-menopausal estrogen treatments may reduce the risk of cardiovascular calcification when administered within the first 5 years of menopause (55, 56). While several recent studies suggest that initiation of estrogen repletion outside of this time period may not confer optimal protection against a myriad of CV complications, the timing, type, and dosing regimens of estrogen that confer vasculo-/valvulo-protection remains a very active field of investigation (57, 58).

**Pre-clinical Observations**

Given the increased prevalence of subclinical and clinical CVD occurring within first decade following menopause (59, 60), a large amount of effort has been put into understanding the interplay between exposure to either endogenous or exogenous estrogens and several of the abovementioned pathophysiological signaling cascades.

*in vitro*, estrogen signals through its binding to cytosolic estrogen receptors (such as estrogen receptor α or β), estrogen binding proteins (EBPs), or membrane G-protein-coupled estrogen receptors (Gpr30) (see Figure 2) (61–63). Through a myriad of genomic and non-genomic effects, estrogens can suppress a variety of molecular processes known to drive cardiovascular calcification, including repression of receptor-activator of nuclear factor κB ligand (RANKL) (47, 64) and NFκB signaling, suppression of NADPH oxidase activity in resident cells and inflammatory infiltrates (65, 66) and suppression of p53 (67). Importantly, estrogens do not exert their effects solely by negative regulatory mechanisms, and treatment of cells or animals with exogenous estrogens can drive expression of antioxidant enzymes (in cytosolic, mitochondrial, and lysosomal compartments), and increase nitric oxide synthase activity and expression, both of which have been implicated as key protective mechanisms in cardiovascular calcification (Figure 2) (68–70).

*in vivo*, endogenous estrogen levels are critical for protection against cardiovascular calcification at multiple sites, as surgical ovariectomy in young mice results in accelerated development of advanced calcified lesions in both aortic and aortic valve tissue (14). It is likely that a major mechanism whereby estrogen exerts its protective effects is via the suppression of TGF-β-dependent extracellular matrix production and accumulation and downregulation of non-collagenous proteins (71) in cardiovascular lesions, both of which likely serve to prevent increases in micro-environmental stiffness that increase the propensity for apoptosis in response to sustained elevations in TGF-β (72). The interactions between sex hormones and TGF-β signaling are remarkably complex and context dependent, however, and entire reviews have focused on this topic and unanswered questions in the field (73). Furthermore, given previous work suggesting that TGF-β can reciprocally inhibit estrogen receptor signaling via a canonical smad4 interaction (74, 75), the extent to which systemic estrogens can be increased to win over this interplay remains unclear. Given clinical observations of disproportionately augmented TGF-β signaling and fibrosis in women (which is not associated with increases in deposition of dystrophic calcific deposits) (15), it is evident that the net impact of sex hormones on the molecular and phenotypic sequelae of TGF-β signaling will be paramount to the advancement of pharmacotherapies targeting valvular stenosis.
These estrogenic effects are independent of the Y chromosome, as atherosclerosis, vascular calcification, and bone growth were accelerated in a man with estrogen receptor dysfunction (76). Since testosterone is converted to estrogen by aromatase in both females and males, additional insights related to the role of estrogenic signaling in men can be gleaned from studies in which aromatase inhibition was administered. Here, inhibition of aromatase reduced vascular dilatation in men (77, 78), suggesting the net impact of endogenous “testosterone-derived” estrogens is protective in men. Furthermore, we are not aware of additional clinical evidence that short term use of aromatase inhibitors bring benefit for reducing cardiovascular disease incidence in the elderly male patients with low levels of androgen (i.e., attempts to restore testosterone levels through prevention of its degradation) (78, 79). Complementing these data supporting a net protective effect of aromatase-derived estrogens, administration of aromatase inhibitors for 5 years in women (to reduce the recurrence of estrogen-receptor positive breast cancer), also appears to increase incidence of cardiovascular disease (80).

ROLE OF ANDROGENS IN THE REGULATION OF CARDIOVASCULAR CALCIFICATION

Clinical Observations
Numerous studies have shown that, in general, testosterone levels decline relatively linearly after the third decade of life, and can be reduced by more than 50% beyond the sixth decade of life. While the decline in free testosterone is coarsely and inversely related to cardiovascular event rates, causal relationships between changes in testosterone levels and cardiovascular disease remains complicated and highly context dependent (81, 82).

Currently, the vast majority of scientific literature would suggest that supraphysiological levels of testosterone—such as those observed in athletes aiming to improve performance—results in significantly higher levels of coronary artery atherosclerosis compared to non-users of the same age (83–85). Reciprocally, hypogonadal men (testosterone levels <300 ng/dL) have an increased risk of numerous cardiovascular events and complications (86, 87). Of the handful of controlled clinical trials completed to date, most suggest that restoring testosterone levels...
to mid-normal range does not increase cardiovascular event rates during most follow-up periods (82, 88). Such interventions may, however, increase the volume of non-calcified coronary lesions (89), suggesting that normal levels of testosterone may be pro-atherogenic but not pro-osteogenic/-calcific.

**Pre-clinical Observations**

**Androgens**

Numerous studies have probed the interactions between androgen signaling and a variety of pathophysiological signaling cascades in cardiovascular tissues, which have in part been a significant contributor to the controversy surrounding their net impact on cardiovascular diseases. In the context of regulating valvar and vascular disease, several studies have demonstrated a clear role for androgens in the promotion of calcific nodule formation through increasing levels of reactive oxygen species (66, 90–92), repressing PPARγ signaling (93–95), and increasing osteogenic signaling (88, 96, 97) (Figure 2). In line with the aforementioned clinical observations in hypogonadal men, however, physiological levels of androgens may reduce vascular calcification by sustaining eNOS activity (23, 98, 99), reducing TGFβ signaling (100, 101), through the suppression of p53-dependent cellular senescence (67, 102), prevention of cellular apoptosis (91, 103, 104), reducing RANKL signaling (105), suppression of local inflammatory signaling (106–110), and attenuation of pro-thrombotic factor activity (111, 112) (Figure 2).

**PROTECTIVE ANDROGENS vs. PROTECTIVE ANDROGEN-DERIVED ESTROGENS**

Similar to aging humans, lower serum testosterone is associated with increased risk of cardiovascular calcification in experimental animals and is attenuated by long-term androgen repletion (98, 113). The biological interpretation of this effect is complicated, however, given the fact that both endogenous and exogenous testosterone can be converted to estrogen by aromatase enzymes (114, 115). Seminal studies showing that androgen receptor-dependent signaling has a deleterious impact on CV calcification (via genetic inactivation of the androgen receptor) combined with reports of augmented vascular calcification in men with spontaneous loss-of-function mutations in estrogen receptors also suggests that testosterone-derived aromatases are an underappreciated factor when considering the net impact of androgen signaling on advanced vascular disease (79, 80, 96).

**HORMONE-INDEPENDENT EFFECTS OF ORGANISMAL SEX: THE ROLE OF THE CHROMOSOMAL COMPLEMENT**

Sex hormones aside, the sex chromosomes—the most fundamental and intrinsic determinant of organismal sex—is also likely to be a significant determinant of propensity for cardiovascular calcification. Both X and Y chromosomes have strong linkage associations with cardiovascular disease risk factors such as hypertension, cardiovascular inflammation, immune biology and macrophage function, and organismal metabolism (116–120). Perhaps most critically, cells derived from XX or XY organisms which are treated with identical in vitro conditions show differences in proliferation, fibrosis, and apoptosis in response to various agonists (121, 122). These changes are not restricted solely to vascular tissues, as osteogenic signaling and responses to various agonists also differ in aortic valve interstitial cells from XX and XY animals (123). Thus, while the Y chromosome may be referred to as a “non-recombinating desert” in some biological circles (124), its sustained phenotypic impact is of undeniable importance in cardiovascular tissues.

**CONCEPTUAL GAPS AND CONTROVERSIES IN THE FIELD OF CARDIOVASCULAR CALCIFICATION**

While tremendous advances have been made in our understanding of cardiovascular calcification over the past several decades, several major gaps remain in our efforts to translate and apply both biological and clinical discoveries to the care of an individual patient.

As appropriate with the scope of this review, one could readily argue that the field’s greatest gap relates to our understanding of the impact of biological sex and the sex steroid hormonal milieu on phenotypic and clinical outcomes in diseases where vascular, valvar, or microvascular calcification are of clinical importance. As the role of this critical context becomes clearer with appropriately controlled and sex-balanced pre-clinical and clinical investigation (125–127), we will undoubtedly gain deeper insights into both the pathobiological underpinnings and potential efficacious therapeutic interventions in men and women suffering from calcific cardiovascular diseases.

Perhaps the greatest controversy in the field of cardiovascular calcification—which is not necessarily exclusive from our understanding of biological sex—is the contexts in which ectopic calcification is driven by non-osteogenic or osteogenic mechanisms. More specifically, while an overwhelming body of evidence suggests that the osteogenic signaling cascades described in this review are present in calcifying tissues from the vast majority of patients with cardiovascular calcification, clinical observations at the time of surgery or autopsy suggest that bone matrix is only evident in a relatively small fraction of this patient population (e.g., 15–25%) (128). Thus, how the cellular decision is made to initiate maladaptive, osteogenic “response to injury” at the earliest stages of microcalcific nodule formation (129) that propagates to true “ectopic bone” or alternatively expands due to progressive and persistent cellular apoptosis to form an amorphous, calcific deposit (130–133) with merely associative increases in osteogenic signaling remains remarkably elusive.

Finally, the role of the biological context of organismal age (and its fundamental biological determinants including changes in sex steroid hormones) in dictating these decisions is only beginning to be understood. While there has been a longstanding association between cellular senescence and tissue calcification [stemming from seminal work by Shanahan et al.]
(134–137) more recent work suggests that the pharmacological targeting and/or clearance of senescent cells may also be a viable strategy for slowing progression of vascular calcification and dysfunction (136). The postulate that targeting fundamental biological mechanisms of aging may be a viable strategy to delay onset or prevent progression of cardiovascular calcification is supported by intriguing observation that biomarkers of biological age (e.g., telomere length) are stronger predictors of incidence of valvular heart disease than chronological age (138).

**PERSPECTIVES ON THE FUTURE OF THE FIELD OF CARDIOVASCULAR CALCIFICATION AND STRATEGIES FOR ADDRESSING THE EFFECTS OF SEX**

While the field of cardiovascular calcification has made tremendous strides in advancing our understanding of osteogenic and non-osteogenic mechanisms contributing to ectopic calcium accrual over the past two decades, it is our opinion that the greatest advances—both scientifically and clinically—will be made in the near future by exploring the context of sex and sex hormones in these phenomena. While many may consider this to be too bold of a statement, it stands on a firm foundation of both clinical and biological reports demonstrating clear sex- and sex hormone-driven differences in the progression of calcific cardiovascular diseases and a glaring lack of success in viable pharmacological strategies to mitigate cardiovascular calcification in elderly persons.

While the National Institutes of Health now mandates consideration of sex as a biological variable in all studies that receive funding (e.g., from pre-clinical animal investigation to human trials), there have not been consistent requirements from publishers and journals requiring reporting of data by sex. Consequently, we would make the following additional suggestions to drive discussion of true “best practices” and accelerate development of critical insights into mechanisms underlying cardiovascular calcification in future studies. First, we suggest that in vitro studies should include independent cell lines derived from each sex of the species being studied, which will allow for characterization of the impact of chromosomal complement and differing epigenetic demarcations in the absence of the sex-steroid and systemic hormonal milieu. With the emergence of evidence that cell line immortalization can drive X and Y chromosomal reconfiguration (139) and the absence of data demonstrating whether such phenomena eliminates sex-dependent molecular responses to exogenous stressors, we also advocate for the use of primary cell lines until comprehensive characterizations of cell phenotype and response are available. Second, we suggest that all sex-disaggregated data should be available within manuscripts and/or online supplements, and that studies should be designed to detect sex differences with appropriate statistical power in an a priori manner. In clinical conditions in which a disease occurs predominantly in one sex vs. the other, we feel a minimum recommendation of having the experimental sample composition be reflective of the sex distribution within the patient population of interest is reasonable. Finally, execution of appropriate hormonal depletion, repletion, or crossover studies would represent a major advance in the field. By appropriate, we refer not only to absolute hormonal levels but also to timing of repletion/depletion (i.e., initiation of the insult later in life, similar to what occurs in humans).

While we believe few investigators would argue that the abovementioned recommendations directly align with the foundational principles of scientific rigor, we are acutely aware that the logistics of implementing such recommendations must be addressed. While doubling the scope and scale of ongoing research projects is neither feasible nor sustainable, we would argue that generation of pre-clinical and clinical datasets that do not inform either the pathobiological underpinnings or clinical care of half of the world’s population reduces the relevance and impact of scientific investigation around the globe. At present, we believe there are few viable arguments against the intentional and appropriate inclusion (and subsequent disaggregated presentation) of data from both sexes in studies of cardiovascular calcification, as the number of samples required for demonstrating sex differences should not increase dramatically when truly qualitatively different trends are uncovered. We acknowledge that discovery of such dichotomous sex responses can often spur new lines of investigation that are beyond the scope of the existing project and subsequently require support through additional funding mechanisms. Critically, we commend NIH and several other funding entities for creation of supplemental research awards devoted to supporting more detailed investigation of mechanisms underlying unexpectedly discovered sex differences, as well as creation of recent RFAs that prioritize identification of novel sex differences in cardiovascular calcification and disease.

Ultimately, we feel that appropriately designed and executed clinical studies—including both men and women potentially with independent outcome measures in each sex (e.g., not only valvular function as a primary outcome but predominantly calcification in men and fibrosis in women as secondary outcomes) is an essential step in ensuring that the utility of sex in predicting therapeutic efficacy and effectiveness across the translational spectrum. While beyond the scope of this review [and covered recently in Sritharen et al. (14)], emerging data strongly suggest that incoming risk profiles, outcomes for surgical valve replacement, outcomes for transcatheter valve replacement, and comorbid condition frequency following disease diagnosis differ robustly amongst men and women, and can serve as a critical catalyst for driving impactful investigation in the biological mechanisms underlying such observations.

**SUMMARY**

The clinical presentation, biological underpinnings, and molecular interactions with sex hormones and biological sex, and ultimate strategies to therapeutically prevent or slow...
progression of cardiovascular calcification differ dramatically between men and women. While in the United States, the National Institutes of Health (NIH) mandate for inclusion of both sexes in research will undoubtedly serve to advance our understanding of these differences, it is our hope that this review will spur additional genuine interest in understanding critical biological and clinical contexts—including, but not limited to, organizational sex—and drive transformative advances in the strategies and tools needed to reduce the growing global burden of calcific vascular and valvular diseases.

REFERENCES

1. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. (2006) 17:5267–73. doi: 10.1681/ASN.2006080925
2. Ruiz JL, Hutcheson JD, Aikawa E. Cardiovascular calcification: current controversies and novel concepts. Cardiovasc Pathol. (2015) 24:207–12. doi: 10.1016/j.carpat.2015.03.002
3. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. (2010) 7:528–36. doi: 10.1038/nrcardio.2010.115
4. Shiio I. Molecular mechanisms of vascular calcification. Clin Calcium. (2010) 20:1611–9. doi: 10.1007/s12046-010-0270-9
5. Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Mechanisms of minimal arterial calcification in diabetes. Curr Pharm Des. (2014) 20:5870–83. doi: 10.2174/138161282066140212214051
6. Pillai CL, Li S, Romay M, Lam L, Lu Y, Huang J, et al. Cardiac fibroblasts adopt osteogenic fates and can be targeted to attenuate pathological heart calcification. Cell Stem Cell. (2017) 20:218–32.e5. doi: 10.1016/j.stem.2016.10.005
7. Nakahara T, Dweck MR, Narula N, Pisapia D, Narula J, Strauss HW. Coronary artery calcification: from mechanism to molecular imaging. JACC Cardiovasc Imaging. (2017) 10:582–93. doi: 10.1016/j.jcmg.2017.03.005
8. Hou M, Song Y, Li Z, Liao C, Ou JS, Yu H, et al. Curcumin attenuates osteogenic differentiation and calcification of rat vascular smooth muscle cells. Mol Cell Biochem. (2016) 420:151–60. doi: 10.1007/s11010-016-2778-v
9. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. (2001) 31:509–19. doi: 10.1016/S0891-5849(01)00610-4
10. Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, Bass J, et al. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation. (2004) 110:3270–5. doi: 10.1161/01.CIR.0000147610.41984.E8
11. Masjedi S, Ferdous Z. Understanding the role of sex in heart valve and major vascular diseases. Cardiovasc Eng Technol. (2015) 6:209–19. doi: 10.1007/s13239-015-0226-x
12. Thaden JJ, Nkomo VT, Suri RM, Malesszowski JJ, Soderberg DJ, Clavel MA, et al. Sex-related differences in calcific aortic stenosis: correlating clinical and echocardiographic characteristics and computed tomography aortic valve calcification score to excised aortic valve weight. Eur Heart J. (2016) 37:693–9. doi: 10.1093/eurheartj/ehv560
13. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cuffe C, Malouf J, Araoz PA, et al. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. Circ Cardiovasc Imaging. (2013) 6:40–7. doi: 10.1161/CIRCIMAGING.112.980952
14. Snitharen Y, Enriquez-Sarano M, Schaff HV, Casaclang-Verzosa G, Miller JD. Pathophysiology of aortic valve stenosis: is it both fibrocalcific and sex specific? Physiology. (2017) 32:182–96. doi: 10.1152/physiol.00025.2016
15. Simard L, Cote N, Dagenais F, Mathieu P, Couture C, Trahan S, et al. Sex-related discordance between aortic valve calcification and hemodynamic severity of aortic stenosis: is valvular fibrosis the explanation? Circ Res. (2017) 120:681–91. doi: 10.1161/CIRCRESAHA.116.309306
16. Rodondi N, Taylor BC, Bauer DC, Lui LY, Vogt MT, Fink HA, et al. Association between aortic calcification and total and cardiovascular mortality in older women. J Intern Med. (2007) 261:238–44. doi: 10.1111/j.1365-2976.2007.01769.x
17. Estublier C, Chapurut R, Szulc P. Association of severe disc degeneration with all-cause mortality and abdominal aortic calcification assessed prospectively in older men: findings of a single-center prospective study of osteoporosis in men. Arthritis Rheumatol. (2015) 67:1295–304. doi: 10.1002/art.39055
18. Liyanage l, Lee NJ, Cook T, Herrmann HC, Jagasia D, Litt H, et al. The impact of gender on cardiovascular system calcification in very elderly patients with severe aortic stenosis. Int J Cardiovasc Imaging. (2016) 32:173–9. doi: 10.1007/s10554-015-0752-5
19. Yang K, Davis HR, Arbustini E, Verzani R. Sex differences in coronary artery disease: pathological observations. Atherosclerosis. (2015) 239:260–7. doi: 10.1016/j.atherosclerosis.2015.01.017
20. Weiss RM, Miller JD, Heistad DD. Fibrocalcific aortic valve disease: opportunity to understand disease mechanisms using mouse models. Circ Res. (2013) 113:209–22. doi: 10.1161/CIRCRESAHA.113.300153
21. Miller JD, Weiss RM, Heistad DD. Aortic valve stenosis: methods, models, and mechanisms. Circ Res. (2011) 108:1392–412. doi: 10.1161/CIRCRESAHA.110.234138
22. Dutta P, and Lincoln J. Calcific aortic valve disease: a developmental biology perspective. Circ Cardiol Rep. (2018) 20:21. doi: 10.1016/j.circrep.2018-08-0968-9
23. Liu AC, Gottlieb AI. Transforming growth factor-beta regulates in vitro heart valve repair by activated valvular interstitial cells. Am J Pathol. (2008) 173:1275–85. doi: 10.2353/ajpath.2008.080365
24. Gomez-Stallons MV, Wirrig-Schwendeman EE, Hassel KR, Conway SJ, Yutze KE. Bone morphogenetic protein signaling is required for aortic valve calcification. Arterioscler Thromb Vasc Biol. (2016) 36:1398–405. doi: 10.1161/ATVBAHA.116.307526
25. Zhang M, Sara JD, Wang FL, Liu LP, Su LX, Zhe J, et al. Increased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patients. Cardiovasc Diabetol. (2015) 14:64. doi: 10.1186/s12933-015-0214-3
26. Shao JS, Ayl ZA, Lai CE, Cheng SL, Cai J, Huang E, et al. Vascular Bmp Mx2 Wnt signaling and oxidative stress in arterial calcification. Ann NY Acad Sci. (2007) 1117:40–50. doi: 10.1196/annals.1402.075
27. Yung LM, Sanchez-Duffhues G, Ten Dijke P, Yu PB. Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovasc Res. (2015) 108:278–87. doi: 10.1093/ctr/ctr221
28. Sun L, Rajamannan NM, Sacks P. Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS ONE. (2013) 8:e64443. doi: 10.1371/journal.pone.0084433
29. Papharaklambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med. (2007) 17:48–54. doi: 10.1016/j.tcm.2006.11.005
30. Caisar A, Lehoux S, Ungvari Z. Hemodynamic forces, vascular oxidative stress, and regulation of BMP-2/4 expression. Antioxid Redox Signal. (2009) 11:1683–97. doi: 10.1089/ars.2008.2401
31. Malhotra R, Burke MF, Martyn T, Shakartzki HR, Thayer TE, O’Rourke C, et al. Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix GlA protein deficiency. PLoS ONE. (2015) 10:e0117098. doi: 10.1371/journal.pone.0117098

AUTHOR CONTRIBUTIONS

All authors contributed to the drafting and revision of the manuscript and concepts expressed herein.

FUNDING

This work was supported in part by grants from the NIH U54 AG 44170, R01 AG 053832, R01 HL 141819, and the Mayo Foundation.
32. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. (2003) 14:1559–67. doi: 10.1097/01.asn.0000086404.57780.DD

33. Freedman BI, Bowden DW, Ziegler JT, Langefeld CD, Lehtinen AB, Rudock ME, et al. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res. (2009) 24:1719–27. doi: 10.1002/jbmr.090501

34. Kanno Y, INTO, Lowenstein CJ, Matsushita K. Nitric oxide regulates vascular calcification by interfering with TGF-β signalling. Cardiovasc Res. (2008) 77:221–30. doi: 10.1093/cvr/cvm049

35. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha driven ROS- and COX2-dependent mechanism. J Pharmacol Exp Ther. (2015) 356:2591–602. doi: 10.1124/jpet.115.216846

36. Gao Y, Huang E, Zhang H, Wang J, Wu N, Chen X, et al. Crosstalk of bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res. (2009) 24:1719–27. doi: 10.1002/jbmr.090501

37. Akwah E. Extracellular vesicles in cardiovascular disease: focus on vascular calcification. Front Cardiovasc Med. (2017) 4:78. doi: 10.3389/fkcm.2017.00078

38. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha driven ROS- and COX2-dependent mechanism. J Pharmacol Exp Ther. (2015) 356:2591–602. doi: 10.1124/jpet.115.216846

39. Chen NX, O’Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification cascade is regulated by TNF-alpha-dependent signals in osteoblastic cells. J Bone Miner Res. (2008) 23:1978–85. doi: 10.1359/bjr.080604

40. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. (2004) 15:2857–67. doi: 10.1097/01.asn.0000149600.01353.28

41. Chen NX, O’Neill RD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. (2008) 23:1978–85. doi: 10.1359/bjr.080604

42. Kapustin AN, Chatrou ML, Droz dov I, Zheng Y, Davidson SM, Soong D, et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res. (2015) 116:1312–23. doi: 10.1161/CIRCRESAHA.116.305012

43. Krohn JB, Hutcheson JD, Martinez-Martinez E, Aikawa E. Extracellular vesicles in cardiovascular calcification: expanding current paradigms. J Physiol. (2016) 594:2895–913. doi: 10.1113/jphysiol.2015.271338

44. Hutcheson JD, Goetzsch C, Bertazzo S, Maldonado N, Ruiz JL, Geh W, et al. Gene expression and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques. Nat Mater. (2016) 15:335–43. doi: 10.1038/nmat4519

45. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol. (2010) 21:101–12. doi: 10.1681/asn.2009060640

46. Jansen F, Xiang X, Werner N. Role and function of extracellular vesicles in calcific aortic valve disease. Eur Heart J. (2017) 38:2714–27. doi: 10.1093/eurheartj/ehx477

47. Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins CC. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vasc Pharmacol. (2016) 82:30–40. doi: 10.1016/j.vph.2016.02.003

48. Kaden JJ, Kilic R, Sarikoc A, Hagn S, Lang S, Hoffmann U, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med. (2005) 16:869–72. doi: 10.3892/ijmm.16.5.869

49. Yu Z, Seya K, Daitoku K, Motomura S, Fukuda I, Furukawa K. Tumor necrosis factor-alpha accelerates the calcification of human aortic valve intercellular cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway. J Pharmacol Exp Ther. (2011) 337:16–23. doi: 10.1124/jpet.110.177915

50. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, et al. Aortic MxS2- Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic LDLr−/− mice. Arterioscler Thromb Vasc Biol. (2007) 27:2589–96. doi: 10.1161/ATVBAHA.107.135668

51. Jousslaht P, Vartiaenen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. (1999) 99:1165–72. doi: 10.1161/01.CIR.99.9.1165

52. Appelman Y, van Rijn BB, Ten Haaf ME, et al. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res. (2009) 24:1719–27. doi: 10.1002/jbmr.090501
sex differences in cv calcification: the role of estrogen. Exp Gerontol. (2017) 97:38–48. doi: 10.1016/j.exger.2017.07.016

Nezvati E, Shafiqhi M, Bakhtian KD, Treiber H, Fandino J, Fathi AR. Estrogen induces nitric oxide production via nitric oxide synthase activation in endothelial cells. Acta Neurochir Suppl. (2015) 120:141–5. doi: 10.1007/978-3-319-04891-6_24

Richards J, El-Hamamsy I, Chen S, Sarang Z, Sarathchandra P, Yacob MH, et al. Side-specific endothelial-dependent regulation of aortic valve calcification: interplay of hemodynamics and nitric oxide signaling. J Pathol. (2013) 182:1922–31. doi: 10.1002/path.10.03.01.037

Donley GE, Fitzpatrick LA. Noncollagenous matrix proteins controlling mineralization; possible role in pathologic calcification of vascular tissue. Trends Cardiovasc Med. (1998) 8:199–206. doi: 10.1016/S1050-1738(98)00014-0

Zhang et al. Sex Differences in CV Calcification

88. Lopes RA, Neves KB, Pestana CR, Queiroz AL, Zanotto CZ, Chignalia AZ, et al. Ablation of aromatase inhibition 2013: clinical state of the art. J Androl. (2016) 37:3569–75. doi: 10.1093/jcar/ehv439

89. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. (2017) 317:708–16. doi: 10.1001/jama.2016.21043

90. Chistikov DA, Miyasoeido VA, Melnichenko AA, Grechko AV, Orekhov AN. Role of androgens in cardiovascular pathology. Vas Health Risk Manag. (2018) 14:283–90. doi: 10.2147/VHRM.S173259

91. Lucas-Herald AK, Alves-Lopes R, Montezano AC, Ahmed SF, Touyz RM. Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. Clin Sci. (2017) 131:1405–18. doi: 10.1042/CS20170090

92. Skogasterrna C, Hotzen M, Rane A, Ekstrom L. A supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. Eur J Prev Cardiol. (2014) 21:1049–54. doi: 10.1177/2047487313481755

93. Du J, Zhang L, Wang Z. Testosterone inhibits the activity of peroxisome proliferator-activated receptor gamma in a transcriptional transaction assay. Pharmac. (2009) 6:692–3. doi: 10.1691/ph.2009.9060

94. Sato H, Sugai H, Kuroasaki H, Ishikawa M, Funaki A, Kimura Y, et al. The effect of sex hormones on peroxisome proliferator-activated receptor gamma expression and activity in mature adipocytes. Biol Pharm Bull. (2013) 36:564–73. doi: 10.1248/bpb.b12-00868

95. Altman R, Motton DD, Kota RS, Rutledge JC. Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vascul Pharmacol. (2008) 48:76–84. doi: 10.1016/j.vph.2007.12.002

96. Cho JJ, Cadet R, Salamon E, Martione K, Stefano GB. The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men. Med Sci Monit. (2003) 9:RA65–8.

97. Vasconcellos A, Pronsato L, Ronda AC, Boland R, Milanesi L. Role of 17beta-estradiol and testosterone in apoptosis. Steroids. (2011) 76:1223–31. doi: 10.1016/j.steroids.2011.08.001

98. Ota H, Aikihisa M, Aikyoshi T, Kayho T, Setou M, Ogawa S, et al. Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1. PLoS ONE. (2012) 7:e29598. doi: 10.1371/journal.pone.0029598

99. Yu J, Aikihisa M, Eto M, Koizumi H, Hashimoto R, Ogawa S, et al. Src kinase mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochem Biophys Res Commun. (2012) 424:538–43. doi: 10.1016/j.bbrc.2012.06.151

100. Chung CC, Hsu RC, Kao YH, Liou JP, Lu YY, Chen YJ, Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-beta and angiotensin II signaling. Int J Cardiol. (2014) 176:386–93. doi: 10.1016/j.ijcard.2017.07.075

101. Ikeda Y, Aihara K, Sato T, Akaille M, Yoshizumi M, Suzuki Y, et al. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J Biol Chem. (2005) 280:29961–6. doi: 10.1074/jbc.M411942000

102. Altieri P, Barisone C, Lazzarini E, Garuti A, Bezante GP, Canepa M, et al. Testosterone antagonizes doxorubicin-induced senescence of cardiomyocytes. J Am Heart Assoc. (2016) 5:e002383. doi: 10.1161/JAHA.115.002383

103. Zhu D, Hadoke PW, Wu J, Vesey AT, Lerman DA, Dweck MR, et al. Ablation of aromatase inhibition on lipids and inflammatory markers of senescence of cardiomyocytes. J Am Heart Assoc. (2016) 5:e002383. doi: 10.1161/JAHA.115.002383

104. Lopes RA, Neves KB, Pestana CR, Queiroz AL, Zanotto CZ, Chignalia AZ, et al. Testosterone induces apoptosis in vascular smooth muscle cells via endothelial NO production and oxidative stress. J Endocrinol. (2015) 62:228–35. doi: 10.1111/j.1365-2265.2005.02205.x
107. Freeman BM, Mountain DJ, Brock TC, Chapman JR, Kirkpatrick SS, Freeman MB, et al. Low testosterone elevates interleukin family cytokines in a rodent model: a possible mechanism for the potentiation of vascular disease in androgen-deficient males. J Surg. Res. (2014) 190:319–27. doi:10.1016/j.surg.2014.03.017

108. Zhang X, Wang LY, Jiang TY, Zhang HP, Dou Y, Zhao JH, et al. Effects of testosterone and 17-beta-estradiol on TNF-α-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci. (2002) 71:15–29. doi:10.1016/S0024-3205(02)01567-9

109. Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K. Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett. (2002) 530:129–32. doi:10.1016/S0014-5793(02)03440-3

110. Zhang et al. Sex Differences in CV Calcification

111. Glueck CJ, Friedman J, Hafeez A, Hassan A, Wang P. Testosterone therapy, thrombophilia, and hospitalization for deep venous thrombosis-pulmonary embolus, an exploratory, hypothesis-generating study. Med Hypotheses. (2015) 84:341–3. doi:10.1016/j.mehy.2015.01.020

112. Brooks AM, Nelson ME, Sacks FM, et al. Effects of soy protein and isoflavones on cardiovascular disease risk factors: results from the Growing Older Albanian Study (GOALS). Circulation. (2000) 101:1876–84. doi:10.1161/01.CIR.101.16.1876

113. Li R, Meng X, Zhang Y, Wang T, Yang J, Niu Y, et al. Testosterone improves erectile function through inhibition of reactive oxygen species generation in castrated rats. PLoS ONE. (2016) 4:e2000. doi:10.7717/plosone.2000

114. Cooke PS, Nanjappa MK, Ko C, Prins GS, Hess RA. Estrogens in male physiology. Physiol Rev. (2017) 97:995–1043. doi:10.1152/physrev.00018.2016

115. Patel S, Homaei A, Raju AB, Meher BR. Estrogen: the necessary evil for human health, and ways to tame it. Biomed Pharmacother. (2018) 102:403–11. doi:10.1016/j.biopha.2018.03.078

116. Arnold AR, Cassis LA, Eghbali M, Reue K, Sandberg K, Sex hormones and sex chromosomes cause sex differences in the development of cardiovascular diseases. Arterioscler Thromb Vasc Biol. (2017) 37:746–56. doi:10.1161/ATVBAHA.116.307301

117. Ventura-Clapier R, Dworkitz E, Seeland U, Kararigas G, Arnal JF, Neri M. Sex chromosome complement defines diffuse versus focal angiotensin II-induced aortic pathology. Arterioscler Thromb Vasc Biol. (2018) 38:143–53. doi:10.1161/ATVBAHA.117.310035

118. Shioi A, Ikari Y. Plaque calcification during atherosclerosis progression and regression. J Atheroscler Thromb. (2018) 25:294–303. doi:10.5551/jat.RV17020

119. Demer LL, Tinut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol. (2014) 34:715–23. doi:10.1161/ATVBAHA.113.302070

120. Fang K, Chen Z, Liu M, Peng J, Wu P. Apoptosis and calcification of vascular endothelial cell under hyperhomocysteinemia. Med Oncol. (2015) 32:403. doi:10.1007/s12032-014-0403-z

121. Bacakova L, Baudysova M. Vascular smooth muscle cells of male and female rat aorta. Anat Rec. (1999) 253:1181–8. doi:10.1002/(SICI)1097-0185(199910)253:6<1181::AID-AR2>3.0.CO;2-P

122. Bacakova L, Pelliccari C, Bottone MG, Lisa V, Mares V. A sex-related difference in the hypertrophic versus hyperplastic response of vascular smooth muscle cells to repeated passing in culture. Histol Histopathol. (2001) 16:675–84. doi:10.14670/HH-16.675

123. McCoy CM, Nicholas DQ, Masters KS. Sex-related differences in gene expression by porcine aortic valvular interstitial cells. PloS ONE. (2012) 7:e39980. doi:10.1371/journal.pone.0039980

124. Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of sex differences in design and reporting of experimental arterial pathology studies statement from ATVB council. Arterioscler Thromb Vasc Biol. (2018) 38:292–303. doi:10.1161/ATVBAHA.117.309524

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.